JP2001505181A - アレルギー疾患の治療方法 - Google Patents

アレルギー疾患の治療方法

Info

Publication number
JP2001505181A
JP2001505181A JP53267597A JP53267597A JP2001505181A JP 2001505181 A JP2001505181 A JP 2001505181A JP 53267597 A JP53267597 A JP 53267597A JP 53267597 A JP53267597 A JP 53267597A JP 2001505181 A JP2001505181 A JP 2001505181A
Authority
JP
Japan
Prior art keywords
ige
week
patient
serum
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP53267597A
Other languages
English (en)
Japanese (ja)
Inventor
マックグレイシャン，ドナルド，ダブリュ．，ジュニア
シー． アデルマン，ダニエル，
ライマン，ジェームス，ディー．
Original Assignee
ジェネンテク，インコーポレイテッド
ジョンズ ホプキンス ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテク，インコーポレイテッド, ジョンズ ホプキンス ユニバーシティ filed Critical ジェネンテク，インコーポレイテッド
Publication of JP2001505181A publication Critical patent/JP2001505181A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP53267597A 1996-03-12 1997-03-06 アレルギー疾患の治療方法 Pending JP2001505181A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61422096A 1996-03-12 1996-03-12
US08/614,220 1996-03-12
PCT/US1997/003443 WO1997033616A1 (en) 1996-03-12 1997-03-06 Methods for treatment of allergic diseases with ige

Publications (1)

Publication Number Publication Date
JP2001505181A true JP2001505181A (ja) 2001-04-17

Family

ID=24460327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53267597A Pending JP2001505181A (ja) 1996-03-12 1997-03-06 アレルギー疾患の治療方法

Country Status (8)

Country Link
EP (1) EP0904108A1 (es)
JP (1) JP2001505181A (es)
AR (1) AR006202A1 (es)
AU (1) AU726143B2 (es)
CA (1) CA2246427A1 (es)
IL (1) IL126113A0 (es)
WO (1) WO1997033616A1 (es)
ZA (1) ZA971607B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
AU2065801A (en) * 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
GB0016441D0 (en) 2000-07-04 2000-08-23 Pharmagene Lab Limited Therapeutic method
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
CA2445269A1 (en) * 2001-05-03 2002-11-14 Novartis Ag Anti-ige antibody to treat ocular allergies
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN114028569B (zh) * 2021-12-20 2023-04-28 中国医学科学院基础医学研究所 免疫球蛋白IgE在诊断和/或治疗高血压中的用途
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US4940715A (en) * 1988-05-17 1990-07-10 Kissei Pharmaceutical Co., Ltd. 5H-pyrazolo[4,3-A] quinolizin-5-one compounds exhibiting therapeutic activities
JP3156237B2 (ja) * 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトＩｇＥ モノクローナル抗体

Also Published As

Publication number Publication date
IL126113A0 (en) 1999-05-09
WO1997033616A1 (en) 1997-09-18
AR006202A1 (es) 1999-08-11
AU1987597A (en) 1997-10-01
ZA971607B (en) 1998-08-25
AU726143B2 (en) 2000-11-02
CA2246427A1 (en) 1997-09-18
EP0904108A1 (en) 1999-03-31

Similar Documents

Publication Publication Date Title
EP0739214B1 (en) A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
EP0841946B1 (en) Methods for treatment of allergic asthma
JP4590152B2 (ja) 喘息の処置
MXPA98000760A (es) Metodos para el tratamiento del asma alergica
US20020172677A1 (en) Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US20110311520A1 (en) Methods for treatment of allergic asthma
US20210148929A1 (en) Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
KR20130103735A (ko) 사람 인터루킨-13에 대한 항체 및 이의 용도
JP2001505181A (ja) アレルギー疾患の治療方法
JP2021501213A (ja) ＩｇＥ介在アレルギー性疾患の治療
Fick IgE and anti-IgE therapy in asthma and allergic disease
US20040141992A1 (en) Desensitizers
RU2800765C2 (ru) ЛЕЧЕНИЕ АЛЛЕРГИЧЕСКИХ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ IgE
WO1997010004A1 (en) Methods for treatment of interstitial cystitis
Babu et al. Newer therapies for asthma: a focus on anti-IgE
Salagean et al. IgE and Anti-IgE Therapy in Allergic Asthma and Rhinitis
CA2131898A1 (en) Methods and compositions for the modulation of host immune response to allergens